Form 4: Viatris CFO Theodora Mistras Reports Equity Transactions

Viatris Inc.'s Chief Financial Officer, Theodora Mistras, reported the vesting of restricted stock units and dividend equivalent units, alongside associated tax withholdings.

Summary

• Theodora Mistras, Chief Financial Officer of Viatris Inc. (VTRS), reported several equity transactions on March 4, 2026.
• Acquired 31,149 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) at a price of $0.
• Disposed of 17,226 shares of common stock at a price of $14.71 to satisfy tax withholding obligations related to the RSU vesting.
• Acquired 2,935 shares of common stock through the vesting and settlement of Dividend Equivalent Units (DEUs) at a price of $0.
• Disposed of 1,624 shares of common stock at a price of $14.71 to satisfy tax withholding obligations related to the DEU vesting.
• Following these transactions, beneficial ownership of common stock stands at 51,076 shares.
• Beneficial ownership of derivative securities includes 31,149 Restricted Stock Units and 2,934 Dividend Equivalent Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the routine vesting of executive equity compensation, which aligns management incentives with long-term company performance. The transactions are standard and do not indicate any unusual activity.

Positives

• The vesting of RSUs and DEUs indicates the maturation of long-term incentive plans, aligning management's financial interests with shareholder value.
• The CFO's continued beneficial ownership of a significant number of shares and derivative units demonstrates ongoing commitment to the company's performance.

Negatives

• The disposal of shares for tax withholding purposes reduces the CFO's direct equity stake, although this is a standard and expected practice for equity compensation.

Future Outlook

The filing indicates that a portion of the Restricted Stock Units granted on March 4, 2024, is scheduled to vest on March 4, 2027, suggesting continued long-term equity incentives for the CFO.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units and Dividend Equivalent Units, is a standard practice across the pharmaceutical and biotechnology industries to incentivize and retain key executives. The vesting schedule aligns with typical long-term incentive structures designed to foster sustained performance and align executive interests with shareholder value.

Comparison to Industry Standards

• The use of RSUs and DEUs for executive compensation is a common practice among large pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson, reflecting a broad industry standard for aligning executive interests with shareholder value creation over multi-year periods.
• The tax withholding mechanism for vested equity awards is a standard procedure, consistent with practices observed in comparable companies, ensuring compliance with tax obligations upon the realization of income from equity compensation.

Stakeholder Impact

• Shareholders: The vesting of equity awards aligns the CFO's financial interests with shareholder value, as her compensation is tied to the company's stock performance.
• Employees: Standard equity compensation practices can serve as a benchmark for other employees' incentive programs within the company.

Next Steps

• The remaining portion of the Restricted Stock Units granted on March 4, 2024, is scheduled to vest on March 4, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions (vesting of RSUs and DEUs, and associated tax withholdings). These are standard, pre-scheduled events and do not provide new fundamental information about Viatris Inc.'s operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions reflect the ongoing alignment of management incentives with shareholder interests, which is generally a positive, but not a catalyst for a 'buy' or 'sell' decision based solely on this filing.

Keywords

Viatris, VTRS, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Dividend Equivalent Units, CFO, Theodora Mistras